Relay Therapeutics is a clinical-stage biotech with a promising pipeline but a precarious financial profile. The company's reliance on episodic collaboration revenue and escalating R&D costs has led to persistent cash burn, with operating losses widening to -$...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.41-4.8% vs -$0.39 | $350,000-63.5% vs $960,000 |
Q2 2026 May 5, 2026 | -$0.41-17.1% vs -$0.35 | $3M-46.2% vs $6M |
Q1 2026 Feb 26, 2026 | -$0.32+15.8% vs -$0.38 | $7M+41.0% vs $5M |
Q4 2025 Nov 6, 2025 | -$0.43-10.3% vs -$0.39 | — vs $5M |
VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 41,900 shares of the company's stock, valued at approximately $784,000. A number of other
Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
Allianz Asset Management GmbH acquired a new stake in Relay Therapeutics, Inc. (NASDAQ: RLAY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 40,100 shares of the company's stock, valued at approximately $750,000. Other large investors have also recently made changes
Frazier Life Sciences Management L.P. acquired a new position in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,015,693 shares of the company's stock, valued at approximately $19,004,000. Frazier Life Sciences
Benchmark RLAY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Relay Therapeutics, Inc. (RLAY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $19.35 | $3.39B | -12.02 | 53.44% | -1800.58% | -41.12% | — | |
| $122.06 | $10.04B | -33.08 | -16.72% | -285.41% | -21.5% | — | |
| $8.51 | $549.08M | -6.65 | -0.3% | 2.94% | 1.91% | — | |
| $40.85 | $4.77B | -12.81 | — | — | -94.56% | — | |
| $15.55 | $5.4B | -35.34 | — | — | -80.43% | — | |
| $90.00 | $6.83B | -26.87 | -12.38% | -654.43% | -50.62% | — |
Relay Therapeutics, Inc. (RLAY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Relay Therapeutics, Inc. (RLAY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 9, 2026·SEC
May 21, 2026·SEC
Get notified when RLAY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Relay Therapeutics, Inc. (RLAY) stock FAQ — growth, dividends, profitability & financials explained
Relay Therapeutics, Inc. (RLAY) reported $10.3M in revenue for fiscal year 2025.
Relay Therapeutics, Inc. (RLAY) grew revenue by 53.4% over the past year. This is strong growth.
Relay Therapeutics, Inc. (RLAY) reported a net loss of $286.0M for fiscal year 2025.
Relay Therapeutics, Inc. (RLAY) has a return on equity (ROE) of -41.1%. Negative ROE indicates the company is unprofitable.
Relay Therapeutics, Inc. (RLAY) had negative free cash flow of $212.2M in fiscal year 2025, likely due to heavy capital investments.
